Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

(2015) Dean J. Kereiakes et al.   AMERICAN HEART JOURNAL

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

(2015) Christopher P. Cannon et al.   EUROPEAN HEART JOURNAL

Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9

(2015) Quoc-Tuan Le et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial

(2015) Harold Bays et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

(2014) Eli M. Roth et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Reduction of LDL cholesterol by a monoclonal antibody to PCSK9 in rodents and nonhuman primates

(2012) Viktoria Gusarova et al.   Clinical Lipidology

Entry and replication of recombinant hepatitis C viruses in cell culture

(2012) Gabrielle Vieyres et al.   METHODS

Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C virus host cell entry

(2012) Alexander Ploss et al.   Current Opinion in Virology

PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression

(2009) Patrick Labonté et al.   HEPATOLOGY

Genetic and Metabolic Determinants of Plasma PCSK9 Levels

(2009) Susan G. Lakoski et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Human occludin is a hepatitis C virus entry factor required for infection of mouse cells

(2009) Alexander Ploss et al.   NATURE